Working... Menu

Compassionate Use of Omegaven IV Fat Emulsion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00816348
Recruitment Status : Terminated
First Posted : January 1, 2009
Results First Posted : February 9, 2016
Last Update Posted : March 10, 2017
Information provided by (Responsible Party):
Cindy Haller, Northwell Health

Brief Summary:
This is a compassionate use protocol to use intravenous fish oil infusion, Omegaven®, to infants and children with parenteral nutrition-associated liver disease to enable reversal of elevated serum liver enzymes and direct bilirubin (cholestasis).

Condition or disease Intervention/treatment Phase
Cholestasis Total Parenteral Nutrition-induced Cholestasis Drug: Omegaven Phase 2

Detailed Description:

Intravenous lipids are necessary in PN (parenteral nutrition) dependent patients due to their high caloric value and essential fatty acid content. However, parenteral fat emulsions composed of soybean oils (omega 6 fatty acids) have been implicated in predisposing patients to PN associated liver disease.

It is hypothesized that by administering Omegaven®, comprised of fish oil (omega 3 fatty acids) in place of conventional soybean fat emulsion, the progression of PN-associated cholestasis may be prevented or reversed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Compassionate Use of Omegaven IV Fat Emulsion
Study Start Date : December 2008
Actual Primary Completion Date : February 2014
Actual Study Completion Date : February 2014

Arm Intervention/treatment
All subjects will receive Omegaven
Drug: Omegaven
Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.

Primary Outcome Measures :
  1. Level of Bilirubin [ Time Frame: week 2, 3,4,and 8 ]
    measurement of bilirubin level weekly. Available data reported.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Two consecutive direct bilirubin levels of 2 mg/dl or more in a parenteral nutrition dependent infant or child (unable to meet nutritional needs solely by enteral nutrition)
  • Other causes of liver disease have been excluded. A liver biopsy is not necessary for treatment.
  • The patient must have utilized standard therapies to prevent the progression of the liver disease including reduction/removal of copper and manganese from daily PN, trial of enteral feeding if possible, and the use of ursodiol (i.e., Actigall®).

Exclusion Criteria:

  • Documented causes of chronic liver disease other than parenteral nutrition associated liver disease
  • Proven severe advanced liver disease including cirrhosis on biopsy, varices, ascites.
  • An allergy to any seafood product, egg protein, and/or previous allergy to Omegaven®
  • Active coagulopathy characterized by ongoing bleeding or by a requirement for clotting factor replacement (e.g. fresh frozen plasma or cryoprecipitate) to maintain homeostasis
  • Impaired lipid metabolism or severe hyperlipidemia with or without pancreatitis
  • Unstable diabetes mellitus or hyperglycemia
  • Stroke, embolism, collapse and shock, recent MI
  • Cholestasis due to any reason other than parenteral associated liver disease
  • Active new infection at time of initiation of Omegaven®
  • Hemodynamic instability
  • The patient may not be enrolled in any other clinical trial involving an investigational agent (unless approved by the designated physicians on the multidisciplinary team).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00816348

Layout table for location information
United States, New York
Cohen Children's Medical Cenetr of New York at North Shore
Manhasset, New York, United States, 11030
Cohen Children's Medical Center of New York
New Hyde Park, New York, United States, 11040
Sponsors and Collaborators
Cindy Haller
Layout table for investigator information
Principal Investigator: Cindy Haller, MD Cohen Children's Medical Center of New York

Layout table for additonal information
Responsible Party: Cindy Haller, Physician, Northwell Health Identifier: NCT00816348     History of Changes
Other Study ID Numbers: 08-204
First Posted: January 1, 2009    Key Record Dates
Results First Posted: February 9, 2016
Last Update Posted: March 10, 2017
Last Verified: January 2017

Keywords provided by Cindy Haller, Northwell Health:
Parenteral Nutrition Associated Liver Disease

Additional relevant MeSH terms:
Layout table for MeSH terms
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases